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Background
MODY represents a genetically and clinically heterogenous group of 
diabetes subtypes. It is characterized by an autosomal dominant mode 
of inheritance as well as early onset of hyperglycemia due to defects in 
β-cell function and disturbed insulin secretion, whereas insulin action 
is usually not impaired [1,2]. In most populations, mutations in the 
hepatocyte nuclear factor (HNF)-1 alpha gene - resulting in MODY3, 
are the most common cause of MODY [3-7]. In the pediatric population 
however, MODY2 is the most common [8]. In general, the mutations 
have a high penetration, with most cases having diabetes by the age of 
25 [3]. In adolescence and early childhood MODY3 patients may show 
only minimal elevation of their fasting blood glucose but be diabetic 
on the 2 h value in an oral glucose tolerance test [9]. Most cases under 
the age of 10 have normal fasting blood glucose and a normal glucose 
tolerance. There appears to be progressive deterioration in beta cell 
function throughout the life span. As the result, the clinical diagnosis 
of diabetes is being made at the average age of 22 and at that time most 
patients present with polyuria and polydipsia [10]. These symptoms 
are associated with the low renal threshold for glucose, typical for 
MODY3 patients, and they are confirmed by the measurement of 
1,5-anhydroglucitol plasma concentration [11]. Patients with HNF1 
alpha mutations are not only more insulin sensitive than type 2 diabetic 
subjects, but they also have greater insulin secretory response to 
sulfonylureas [12,13]. The replacement of sulfonylureas with metformin 
had caused a dramatic deterioration in glycemic control [14]. Patients 
with HNF 1 alpha mutation presented with a 5-fold increase response to 
a gliclazide than metformin [12]. Sulphonyloureas are still a treatment 
of choice for young MODY3 patients showing excellent results for 
decades. It is important to remember that sulphonyloureas should be 
used with a great caution, by starting with a minimal dose. However the 
slow loss of insulin secretory capacity is progressive and as a result that 
majority of older patients eventually will need insulin.
Women with oligomenorrhea and polycystic ovaries show a 
high incidence of ovulation failure that is linked to insulin resistance 
and related metabolic features. It was shown in a large randomized 
placebo-controlled trial that metformin treatment improves ovulation 
frequency in women with abnormal ovarian function, oligomenorrhea 
and polycystic ovaries [15]. A recent survey indicated that 30% of 
pediatric endocrinologists are considering metformin treatment as 
appropriate for adolescents with PCOS, and 68% of those specialists 
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Abstract
Sulphonyloureas are a treatment of choice for Maturity-Onset Diabetes of the Young type 3 (MODY3) young 
patients with excellent results, although they should be used with a great caution. In adult MODY3 patients 
hypersensitive response to sulphonyloureas and a decreased response to metformin in compare to sulphonyloureas 
were reported.
A case of teenager with MODY 3 and oligomenorhoea, successfully treated with metformin is presented.
A fifteen and a half year-old girl was diagnosed with oligomenorrhoea. Due to detected glucosuria and blood 
glucose (BG) at 267 mg/dl she was referred to a pediatric endocrinologist. She did not present with typical diabetes 
mellitus (DM) symptoms, however she had a three generations family history positive for insulin-dependent DM. 
She presented with a good clinical condition. The underweight (Body mass index 18.7 kg/m2) and discrete hirsutism 
were observed. Glucosuria, ketonuria, BG above 200 mg/dl in 24-h BG profile, and HbA1c 7.1% confirmed the 
diagnosis of DM, and insulinotherapy was initiated. Further diagnostics revealed high C-peptide levels and negative 
diabetes autoantibodies. Due to a low requirement of insulin and a presence of oligomenhorea, insulinotherapy 
was replaced with metformin. Three months after metformin introduction, HbA1c level normalized and menstruation 
cycles became regular. Genetic tests confirmed the diagnosis of MODY3 in the patient and her family. No pathology 
in the morphology and function of the kidneys was found. Due to the positive effect of metformin on regulation of 
menstrual cycles, and the continued high C-peptide level, the treatment with metformin has been continued. During 
the last three years follow-up, HbA1c levels fluctuated between 5.6-5.8% and menstrual cycles have been regular. 
Our case presents that metformin could be an adequate treatment for teenagers with MODY 3 and oligomenorhea/
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consider it for obese adolescents with PCOS [16]. There is some data 
supporting a beneficial effect of metformin in improving ovarian 
function in adolescents [17,18].
The aim of the study is a case presentation of teenager with MODY3 
and oligomenorhoea treated successfully with metformin.
Case Presentation
A fifteen and a half year-old patient visited the office of the general 
physician because of oligomenorrhoea. In basic biochemical tests 
glucosuria was detected (glucose in urine 226 mmol/l), BG level was 
267 mg/dl. The patient was referred to the Department of Pediatric 
and Adolescent Endocrinology. She did not present with any typical 
diabetes symptoms. She was born from a 3rd uncomplicated pregnancy, 
in 37 week of gestation and with 2680 g body weight. She had no 
chronic diseases. Her psychosomatic development appeared to be 
normal. Her menarche occurred when she was 11 years old. Menstrual 
cycles were regular until last year. An amenorrhea has been observed 
for last four months. Her family history was positive for DM, which had 
been diagnosed in her grandmother – father’s mother, her father and 
older brother. Her father has been receiving insulin since adolescence. 
Currently, he is blind due to diabetic retinopathy. He also presents with 
diabetic neuropathy. Other complications are not observed. Patient’s 
older brother was diagnosed with type 1 diabetes mellitus at the age 
of 17. He presented with typical diabetes symptoms, and an intensive 
insulin therapy was administered for the management of his DM.
When the patient was tested in the Outpatient Clinic, 2.5 h after 
meal her BG level was 276 mg%. Glycosuria and ketonuria were also 
detected. Therefore she was admitted to the hospital. During the time 
of admission she was in a good clinical state. However, low body 
weight (Body Mass Index (BMI) 18.7 kg/m2) and discrete hirsutism 
were observed in physical examination. Her height reached level of 50 
percentile in accordance with mid-parental height, body mass was (-) 
8.3% of body weight appropriate for height, pubertal status was stage V 
according to Tanner scale. Presence of glucosuria, ketonuria, BG above 
200 mg/dl in 24-h BG profile (premeal and 2-h postprandial), and 
HbA1c 7.1% confirmed the diagnosis of DM. Other basic biochemical 
tests including acid-base balance were within normal ranges. As an 
initial treatment, diabetic diet and short acting insulin analog for each 
meal were introduced. Normoglycemia was achieved with the daily 
insulin dose of 0.4 IU/kg b.w. In order to establish the type of DM, 
diabetic autoantibodies such as Islet Cell Antibodies (ICA), Glutamic 
Acid Decarboxylase (GAD) antibodies, and Islet Antigen 2 (IA2) were 
measured. They were negative. Moreover C-peptide levels were quite 
high: fasting they presented at 3.5 ng/ml, 2 hours after meal its value 
reached 6.8 ng/ml. Thyroid function presented normal (TSH- 2.36 uIU/
ml, fT4-13.8 pmol/l; N 10-25 pmol/l). Other autoantibodies such as anti-
thyroid peroxidase (18.5 U/ml; N to 60 U/ml) and anti endomysium 
were negative. The patient was referred to the gynecologist but she 
misunderstood this recommendation. 
Due to low daily requirement of insulin and oligomenhorea, a 
decision for the replacement of insulinotherapy with metformin was 
made. This happened one month after the patient was diagnosed with 
DM, when the results of autoantibodies and C-peptide were known. 
Within three months of the treatment with metformin dosage 500 mg 
twice a day, HbA1c level normalized and menstruation cycles became 
regular. At that time, the control level of fasting C-peptide was still high 
and reached 3.39 ng/ml. At the same time we received the results of 
genetic tests that had been performed due to family history positive for 
DM. As the result, heterozygotic mutation in HNF 1 alfa was detected. 
It was discovered that the patient and other living diabetic members 
of her family have P291fsinsC frameshift mutation. Further detailed 
diagnostics of morphology and function of kidneys and other organs 
were performed and no pathology was found. Due to positive effect 
of metformin treatment on the regulation of menstrual cycles and still 
high level of C-peptide we decided to continue with the treatment. For 
the last three years, when checked during the follow-up visits, HbA1c 
has been varied between 5.2-5.8%, menstrual cycles have been regular, 
and patient’s body weight presents stable (Table 1 and Figure 1). Lactic 
acid levels have been checked regularly and stayed within normal 
ranges. Levels of patient’s blood pressure and serum lipids were within 
normal ranges during the observation time. The patient was screened 
for diabetic complications as neuropathy, retinopathy, and nephropathy 
(albuminuria level) and none of them have been detected. The last 
result of patient’s C-peptide after 3 years of treatment with metformin 
has been still high 2.89 ng/ml.
Date HbA1c [%] Height [cm] Body weight [kg]
Oct 2010 7.1 164 50.3
Jan 2011 6.6 165 48
Metformin administration
April 2011 5.7 165 48
June 2011 5.8 165 48
Aug 2011 5.8 165.5 49.5
Nov 2011 5.6 165.5 50
Jan 2012 5.7 165.5 50
April 2012 5.7 165.5 49.5
July 2012 5.6 165.5 49
Sept 2012 5.7 165.5 49
Jan 2013 5.7 165.5 49
March 2013 5.6 165.5 49
June 2013 5.2 165.5 48.8
Sept 2013 5.6 165.5 49
Table 1: The changes of HbA1c and height and body weight values in the patient 
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Figure 1: The clinical outcome of HbA1c and Body Mass Index (BMI) in the 
patient with MODY3 during treatment with metformin.
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Discussion
The type of mutation that has been detected in the presented 
case patient had been previously reported in numerous patients with 
MODY3 [19]. The diagnosis of diabetes in most of the carries of this 
mutation had followed typical diabetes symptoms. Most of them were 
treated with sulfonylureas, the minor part required insulin or only 
diabetic diet. 
In the case presented, DM was diagnosed in adolescence without 
typical diabetes symptoms. It was a chance discovery during the 
diagnostic of oligomenorhhea. At least 20% of MODY3 patients remain 
free of diabetes until their 30s [19-21]. These non-penetrant patients 
have a low BMI and are likely to be sensitive to insulin [9]. Our patient 
was indeed slim and her initial insulin requirement was not high. 
Moreover the mutation came from her father. If the mutation came 
from the mother, diabetes would be diagnosed at a younger age, and 
the treatment would more likely be insulin [20]. 
Early observation showed that HNF1 alfa mutation patients 
were extremely sensitive to the hypoglycemic effects of sulfonylureas 
[14,22,23]. When sulfonylureas were replaced with metformin a 
dramatic deterioration in glycemic control was noticed [14]. Initial 
reports were case reports or small series. Currently there is evidence 
from a randomized cross-over trial in which glycemic responses to 
metformin were compared between MODY3 patients and type 2 DM 
matched for fasting glucose and body mass index [12]. In patients with 
HNF 1 alpha mutation, however there was a 5-fold greater response 
to gliclazide than to metformin, and the response to the sulfonylurea 
was 4-fold greater than that in type 2 patients [12]. Some other 
environmental factors such as obesity and physical activity may affect 
insulin sensitivity and cause an imbalance between insulin secretion 
and insulin demand in MODY3 patients [20]. The patient presented, 
was slim, moreover C-peptide level at the time of the diagnosis was 
high. This fact however did not reflect the progressive deterioration of 
beta cell function but the opposite, and might rather indicate insulin 
resistance. As a matter of fact, MODY3 patients do not exhibit the 
insulin resistance characteristic for type 2 DM and probably due to 
that reason, hypertension and macrovascular disease appears less 
frequently in MODY3 than in type 2 DM [24]. On the other hand, 
microangiopathic complications occur with the same frequency in 
MODY3 and type 2 DM and hyperglycemia is the main predictor of 
these complications. As to confirm the above-cited study we present 
the patient’s father who suffers from progressive diabetic retinopathy 
without clinical signs of macrovascular complications. 
High C-peptide levels and a very good clinical response to metformin 
suggest the insulin resistance as an explanation for oligomenorrhea 
observed in the presented case. Metformin, primarily works by 
inhibiting hepatic glucose output. In addition to suppressing hepatic 
glucose production, metformin increases insulin sensitivity, enhances 
peripheral glucose uptake (by phosphorylating GLUT-4 enhancer 
factor), increases fatty acid oxidation, and decreases absorption of 
glucose from the gastroinstestinal tract [25]. Therefore the effect of 
metformin action is the reduction of glucose and insulin levels. One 
of the hypothesis of metformin action in PCOS is androgens reduction 
follows from insulin reduction as an effect of metformin treatment. 
On the other hand the effect of metformin upon insulin secrtion could 
not be clearly separated from that of weight loss [26]. There are studies 
presenting that metformin treatment improves ovulation frequency 
in as well women as adolescents with abnormal ovarian function, 
oligomenorrhea and polycystic ovaries [15-18]. It is impossible to 
diagnose PCOS in our patient due to lack of ultrasonography assessment 
of ovaries. The coexistence of hiperinsulinism, oligomenorrhoea and 
moreover the normalization of menstruation cycles after metformin 
administration could indicate that the patient could have had a sub-
phenotype of PCOS.
The opportunity to treat our patient with metformin may have 
resulted in early diagnosis of diabetes due to the accidental coexistence 
of oligomenorhhea. At the moment of diagnosis of MODY3, 
administration of sulfonyloureas, which are a treatment of choice, was 
not possible, because of detected high C-peptide levels and therefore 
highly probable hyperexcitability to that treatment [12,23]. Currently 
there is difficult to predict the future of the therapy for the patient, 
because progressive deterioration of beta cell function has been 
reported several times throughout the life of MODY3 patients [19,20]. 
As it is confirmed by the results of metabolic control of diabetes 
during last three years of follow-up treatment, nowadays metformin 
has a real beneficial effect for the teenager with MODY3 and 
oligomenorhhea who has been presented during the case study.
Conclusion
Metformin could be an adequate treatment for teenagers with 
MODY3 and oligomenorhea/PCOS.
This observation has an important clinical value. In MODY3 
teenagers standard treatment with sulfonyureas, which is the treatment 
of choice, should be used with a great caution. The patients with HNF 1 
alpha mutation tend to have an exacerbated response to sulphonylureas. 
Our case presents that sulfonyureas could be replaced with metformin 
with good results of diabetes control and other benefits for ovarian 
function.
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